Article
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance).
Blood advances - 26 Dec 2018
Roboz Gail J, Mandrekar Sumithra J, Desai Pinkal, Laumann Kristina, Walker Alison R, Wang Eunice S, Kolitz Jonathan E, Powell Bayard L, Attar Eyal C, Stock Wendy, Bloomfield Clara D, Kohlschmidt Jessica, Mrózek Krzysztof, Hassane Duane C, Garraway Levi, Jané-Valbuena Judit, Baltay Michele, Tracy Adam, Marcucci Guido, Stone Richard M, Larson Richard A
Abstract excerpt
Novel treatment strategies are needed for older patients with acute myeloid leukemia (AML). This randomized phase 2 trial compared the efficacy and safety of 20 mg/m2 of IV decitabine on days 1 to 10 alone (arm A) with those of 1.3 mg/m2 of subcutaneous bortezomib (arm B) on days 1, 4, 8, and 11 for up to 4 10-day cycles followed by monthly 5-day cycles. Previously untreated AML patients age ≥60 years (excluding...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.